Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | MITF | O75030 | 1/20 | 0.73 |
| ▸ | GAA | P10253 | 1/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.73 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442860 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL7143395 | 0.94 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL10715309 | 0.89 | MAPT (0.54) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL633481 | 0.86 | MAOB (0.67) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL29349910 | 0.85 | MAOA (0.52) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL3716891 | 0.85 | MAOA (0.52) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL4092959 | 0.85 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL6290623 | 0.85 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL22289568 | 0.85 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL1271678 | 0.85 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217513-A1 | ACTIVATION OF PLCG2 AS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250051335-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2025-02-13 | — | — | US | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| EP-4368182-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | Consejo Superior De Investigaciones Científicas - CSIC (ES) | 2024-05-15 | — | — | EP | disclosed |
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-16 | — | — | US | disclosed |
| WO-2023281149-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2023-01-12 | — | — | WO | disclosed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2022-09-22 | — | — | US | disclosed |
| US-11286359-B2 | Prepreg and carbon fiber-reinforced composite material | TORAY INDUSTRIES, INC. (JP) | 2022-03-29 | — | — | US | disclosed |
| US-11289238-B2 | Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes | HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) | 2022-03-29 | — | — | US | disclosed |
| WO-2007067781-A2 | 9-MEMBERED HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070135387-A1 | Inhibitors of protein kinases | ABBOTT LABORATORIES | 2007-06-14 | — | — | US | disclosed |
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1546111-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031160-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-04-15 | — | — | WO | disclosed |
| US-6284764-B1 | ANTIPROLIFERATIVE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0113922-A2 | Process for the manufacture of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113921-A2 | Process for the manufacture of stable solutions of cationic methine dyes | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| EP-0113920-A2 | Process for the manufacture of stable solutions of cationic methine dyes, and their use in spin dyeing | BAYER AG (DE) | 1984-07-25 | — | — | EP | disclosed |
| US-3956264-A | Basic azo dyestuffs having indolyl-methyleneamino substituent in the diazo component | BAYER AKTIENGESELLSCHAFT (DT) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078764-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | ALDH1A1 293/4885SMN1; SMN2 121/4885MAPT 101/4885 |
| US-20250051335-A1 | TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS | TTBK1, TTBK2, MAPT | ALDH1A1 3733/4885SMN1; SMN2 180/4885MAPT 3/4885 |
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | ALDH1A1 452/4885SMN1; SMN2 4641/4885MAPT 4311/4885 |
| US-20220298168-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALDH1A1 656/4885SMN1; SMN2 13/4885MAPT 22/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALDH1A1 656/4885SMN1; SMN2 13/4885MAPT 22/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | ALDH1A1 3365/4885SMN1; SMN2 3680/4885MAPT 3743/4885 |
| US-20070135387-A1 | Inhibitors of protein kinases | MAP3K20, PACSIN2, MAP4K2 | ALDH1A1 4438/4885SMN1; SMN2 2618/4885MAPT 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.